Skip to main content
S&P 5007,580.07-1.82%DOW51,770.31-1.09%NASDAQ25,437.00-2.86%BTC$77,415.00+0.36%ETH$2,246.32+1.22%GOLD$3,884.90-3.63%OIL$102.95+0.93%
Smart Investors Daily
SID Premium
TL

NASDAQ · TLX

Telix Pharmaceuticals Limited

Healthcare · Biotechnology

$9.10

Down-$0.41 (-4.31%)

Updated Nov 2, 2026, 1:18 AM

SID Score

4.5/10

Composite research score

Smart Money

58/100

Neutral

Market cap
3.18B
P/E ratio
133.11
Dividend yield
0.00%
52-week range
$7.20 – $13.11
Volume
341.88K
Avg. volume
128.55K

Price performance · TLX

TLX price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 30, 2026

TLX closed at $9.10 after 20 trading sessions, down 16.36% for the selected period.

Last close
$9.10
Period change
-16.36%
Period low
$8.99
Period high
$11.29
Daily close
View OHLC price history
TLX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 30, 2026$9.26$9.26$8.98$9.10341.88K
Oct 29, 2026$9.55$9.60$9.48$9.51211.31K
Oct 28, 2026$9.21$9.285$9.131$9.26244.62K
Oct 27, 2026$8.94$9.06$8.91$9.03224.85K
Oct 26, 2026$9.00$9.01$8.91$8.99323.42K
Oct 23, 2026$9.26$9.295$9.11$9.15413.44K
Oct 22, 2026$9.56$9.605$9.43$9.54734.05K
Oct 21, 2026$10.25$10.25$9.92$10.03879.08K
Oct 20, 2026$10.98$11.24$10.98$11.16304.95K
Oct 19, 2026$10.71$10.85$10.68$10.74249.79K
Oct 16, 2026$10.92$10.94$10.66$10.69324.86K
Oct 15, 2026$10.52$10.59$10.43$10.57220.69K
Oct 14, 2026$10.71$10.77$10.61$10.65223.28K
Oct 13, 2026$11.01$11.01$10.86$10.92350.81K
Oct 12, 2026$11.30$11.385$11.275$11.29266.21K
Oct 9, 2026$11.11$11.26$11.08$11.21313.02K
Oct 8, 2026$11.08$11.10$10.93$11.01390.35K
Oct 7, 2026$11.01$11.14$11.00$11.12817.44K
Oct 6, 2026$10.96$10.96$10.73$10.78235.1K
Oct 5, 2026$10.80$10.91$10.79$10.88235.29K

Latest TLX news

The latest Smart Investors Daily articles mentioning TLX.

Stock researchCompany · Overview

TLX research

Overview

Company profile and research snapshot.

Company profile

Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$20.00
Implied upside
—
Analysts
—
TLX recent ratings
DateFirmRatingTarget
Oct 21, 2026WedbushOutperform—
Sep 25, 2026HC Wainwright & Co.Buy—
Sep 23, 2026WedbushOutperform—
Sep 15, 2026HC Wainwright & Co.Buy—
Sep 14, 2026WedbushOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 25, 2026

Our Pick Of The Best Australian Growth Stocks In October 2026

The US Federal Reserve is widely expected to hold interest rates steady, which keeps global financial conditions tight and puts pressure on slower growing businesses. Australian high growth companies where founders and executives own meaningful stakes can look different in that setting. Management is highly motivated and already focused on expansion. This article highlights three such local stocks, each combining rapid business growth with substantial insider ownership. The three stocks...

Yahoo · Oct 20, 2026

Telix Reports Third Quarter 2026 Financial Performance

MELBOURNE, Australia and INDIANAPOLIS, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) provides a financial update on its commercial and operational performance for the quarter ended September 30, 2026 (Q3 2026). Q3 2026 Highlights1 Group revenue of US$245 million increased 19% over the prior corresponding quarter (Q3 2025) driven by continued strong demand for the commercial portfolio, in line with expectations. September sales drove a higher qua

Yahoo · Oct 19, 2026

Ekalia takes an important step in the deployment of Astatine-211 in the United States through a collaboration agreement with Telix

The joint venture between IBA and Framatome will leverage Telix’s capabilities to accelerate the production and availability of Astatine-211 in the US market. Louvain-la-Neuve, Belgium, Paris, France, Indianapolis, United States, and Melbourne, Australia, October 19th, 2026, 7 a.m. – Ekalia (company in formation), the joint venture combining IBA’s technological expertise (Ion Beam Applications, EURONEXT) with Framatome’s industrial know-how, has entered into a collaboration agreement with Telix

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By